Artwork

Контент предоставлен Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.
Player FM - приложение для подкастов
Работайте офлайн с приложением Player FM !

Pembro improves survival after nephrectomy | Huge news for Urologists

45:57
 
Поделиться
 

Manage episode 421847144 series 3350113
Контент предоставлен Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.

For Urologists, there are not that many papers that come along where we can say - "this will almost immediately change my practice". But KEYNOTE-564 looks like one of those! A large phase III randomised trial of adjuvant pembro following nephrectomy for renal cell carcinoma in patients deemed at higher risk for recurrence. Regular listeners/viewers might remember we discussed this on GU Cast back in August 2021 when the disease-free survival endpoint was published in NEJM, and it would be fair to say we were cautious and kept saying "we need to wait for the overall survival data". Well here we are! Patients who received pembro for one year had a 38% reduced risk of death. Big news!
We are joined again by Dr Alex Kutikov, Urologist at Fox Chase Cancer Centre, who joined us on the original podcast. We are also joined by his colleague GU Medical Oncologist, Dr Matt Zibelman, who has a lot of experience in this area having been an investigator on the IMmotion 010 study. Unfortunately lead author Dr Toni Choueiri could not join us this time but he gets plenty of mentions!
This is a Themed Podcast supported by our Silver Partners, MSD, manufacturers of pembrolizomab, through an educational grant. MSD had no input into the content of this podcast.
Even better on our YouTube channel
Links:
Full NEJM paper
Previous GU Cast on K-564

  continue reading

165 эпизодов

Artwork
iconПоделиться
 
Manage episode 421847144 series 3350113
Контент предоставлен Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.

For Urologists, there are not that many papers that come along where we can say - "this will almost immediately change my practice". But KEYNOTE-564 looks like one of those! A large phase III randomised trial of adjuvant pembro following nephrectomy for renal cell carcinoma in patients deemed at higher risk for recurrence. Regular listeners/viewers might remember we discussed this on GU Cast back in August 2021 when the disease-free survival endpoint was published in NEJM, and it would be fair to say we were cautious and kept saying "we need to wait for the overall survival data". Well here we are! Patients who received pembro for one year had a 38% reduced risk of death. Big news!
We are joined again by Dr Alex Kutikov, Urologist at Fox Chase Cancer Centre, who joined us on the original podcast. We are also joined by his colleague GU Medical Oncologist, Dr Matt Zibelman, who has a lot of experience in this area having been an investigator on the IMmotion 010 study. Unfortunately lead author Dr Toni Choueiri could not join us this time but he gets plenty of mentions!
This is a Themed Podcast supported by our Silver Partners, MSD, manufacturers of pembrolizomab, through an educational grant. MSD had no input into the content of this podcast.
Even better on our YouTube channel
Links:
Full NEJM paper
Previous GU Cast on K-564

  continue reading

165 эпизодов

Все серии

×
 
Loading …

Добро пожаловать в Player FM!

Player FM сканирует Интернет в поисках высококачественных подкастов, чтобы вы могли наслаждаться ими прямо сейчас. Это лучшее приложение для подкастов, которое работает на Android, iPhone и веб-странице. Зарегистрируйтесь, чтобы синхронизировать подписки на разных устройствах.

 

Краткое руководство

Слушайте это шоу, пока исследуете
Прослушать